Addressing rare, toxic downside of immunotherapyOUPblog (blog)One of the most-cited cancer journals, the Journal of the National Cancer Institute features original research from around the world and is internationally acclaimed as the source for the mo… Continue reading
|
MPEG LA invites CRISPR-Cas9 patents to be pooled in a one-stop license
BSI bureau (press release) Pooling the foundational CRISPR patent rights under a single nonexclusive, cost-effective, transparent license will allow the market to focus on the creation of new products and therapies that accelerate and expand CRISPR’s deployment. Just as MPEG LA … |
|
MPEG LA invites CRISPR-Cas9 patents to be pooled in a one-stop license
BSI bureau (press release) Pooling the foundational CRISPR patent rights under a single nonexclusive, cost-effective, transparent license will allow the market to focus on the creation of new products and therapies that accelerate and expand CRISPR’s deployment. Just as MPEG LA … |
|
Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR–T cells patents
Yahoo Finance The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to allogeneic human primary T–Cells that are engineered to be T–Cell Receptor (TCR) deficient and express a Chimeric Antigen Receptor (CAR). |
|
Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR–T Cells Patents
Business Wire (press release) Celyad (Paris:CYAD) (Brussels:CYAD), a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR–T cells. This license … |
News-Medical.net |
Noninvasive PET imaging may predict cancer patients’ immunotherapy response early
News-Medical.net Response to immunotherapy often cannot be measured effectively at early time points by traditional imaging techniques that measure tumor size, such as CT and MRI scans, or those that measure tumor glucose uptake, such as FDG PET, because these … Granzyme B Probe Plus PET Scanning Helps Determine Response To ImmunotherapyMedicalResearch.com (blog) |